A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours
Open Access
- 1 December 2000
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 11 (12) , 1579-1584
- https://doi.org/10.1023/a:1008347630465
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid MalignanciesJournal of Clinical Oncology, 2000
- Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.Journal of Clinical Oncology, 1998
- Matrix Metalloproteinase Inhibitor DrugsEmerging Drugs, 1997
- Matrix metalloproteinase inhibition: A review of anti-tumour activityAnnals of Oncology, 1995
- Matrix Metalloproteinases and Their Inhibitors in Tumor ProgressionaAnnals of the New York Academy of Sciences, 1994
- Clinical Importance of Metalloproteinases and Their InhibitorsaAnnals of the New York Academy of Sciences, 1994
- Regulation of Matrix Metalloproteinase ActivityaAnnals of the New York Academy of Sciences, 1994
- Assessing the Reliability of Two Toxicity Scales: Implications for Interpreting Toxicity DataJNCI Journal of the National Cancer Institute, 1993
- Reporting results of cancer treatmentCancer, 1981